Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

被引：30
作者：
Seyedmousavi, Seyedmojtaba [1 ,2 ]
Verweij, Paul E. [2 ]
Mouton, Johan W. [1 ,2 ]
机构：
[1] Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands
[2] Radboudumc, Dept Med Microbiol, Nijmegen, Netherlands
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 01期
关键词：
isavuconazole; pharmacodynamics; pharmacokinetics; systemic fungal infections; IN-VITRO ACTIVITY; PHARMACODYNAMIC TARGET DETERMINATION; WATER-SOLUBLE PRODRUG; 8 ANTIFUNGAL DRUGS; CRYPTOCOCCUS-GATTII; ASPERGILLUS-FUMIGATUS; DOSE PHARMACOKINETICS; FUNGICIDAL ACTIVITIES; EUROPEAN COMMITTEE; AZOLE ANTIFUNGALS;
D O I：
10.1586/14787210.2015.990382
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The prodrug isavuconazonium sulfate (BAL8557) is an extended-spectrum water-soluble triazole, developed for the treatment of severe invasive and life-threatening fungal diseases. Its active moiety, BAL4815, is a potent inhibitor of ergosterol biosynthesis, resulting in the disruption of fungal membrane structure and function. The active compound shows broad-spectrum of activity and potency against all major opportunistic fungi, such as Aspergillus spp., Candida spp., Cryptococcus spp., Mucorales, Black yeasts and their filamentous relatives and the true pathogenic fungi, including Histoplasma capsulatum and Blastomyces dermatitidis. It is currently in Phase III clinical development for treatment of aspergillosis, candidiasis and mucormycosis, as well as other rare fungi infections. We reviewed the pharmacokinetic and pharmacodynamic characteristics of isavuconazole, and its microbiological and clinical investigation progress in advanced stages of development.
引用
收藏
页码：9 / 27
页数：19
相关论文
共 117 条
[41]  
Heep M, 2007, 17 ANN EUR C CLIN MI
[42]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415
[43]   Emerging opportunistic yeast infections in haematology patients [J].
Hofmeyr, Ann ;
Slavin, Monica A. .
LEUKEMIA & LYMPHOMA, 2006, 47 (09) :1736-1737
[44]   In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba [J].
Illnait-Zaragozi, Maria-Teresa ;
Martinez, Gerardo F. ;
Curfs-Breuker, Ilse ;
Fernandez, Carlos M. ;
Boekhout, Teun ;
Meis, Jacques F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1580-1582
[45]   Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole [J].
Imhof, A ;
Balajee, SA ;
Fredricks, DN ;
Englund, JA ;
Marr, KA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) :743-746
[46]   Resistance to antifungal agents: Mechanisms and clinical impact [J].
Kanafani, Zeina A. ;
Perfect, John R. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (01) :120-128
[47]   In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatis [J].
Kloezen, Wendy ;
Meis, Jacques F. ;
Curfs-Breuker, Ilse ;
Fahal, Ahmed H. ;
van de Sandea, Wendy W. J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (11) :6054-6056
[48]   Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species [J].
Lackner, Michaela ;
de Hoog, G. Sybren ;
Verweij, Paul E. ;
Najafzadeh, Mohammad J. ;
Curfs-Breuker, Ilse ;
Klaassen, Corne H. ;
Meis, Jacques F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) :2635-2642
[49]   Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus [J].
Lepak, Alexander J. ;
Marchillo, Karen ;
VanHecker, Jamie ;
Andes, David R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) :6284-6289
[50]   Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model [J].
Lepak, Alexander J. ;
Marchillo, Karen ;
VanHecker, Jamie ;
Diekema, Daniel ;
Andes, David R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (11) :5642-5648
12345678910